NCT05088395 Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
| NCT ID | NCT05088395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,050 participants |
| Start Date | 2022-05-19 |
| Primary Completion | 2031-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,050 participants in total. It began in 2022-05-19 with a primary completion date of 2031-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort. Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.
Eligibility Criteria
Inclusion Criteria: * Patient treated for cancer at one of the participating center * 18 years old or higher * Signed informed consent form * Patient not deprived of their liberty or under guardianship (including temporary guardianship) * Patient covered by social security scheme * Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up * Other additional criteria will be defined (defining tumor type and clinical setting), by cohort If a biopsy tumor sample is to be taken: * Tumor considered as accessible by biopsy (at the investigator's discretion). * Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion). * No anticoagulant or antiaggregant treatment for the biopsy. Exclusion Criteria : Pregnant and/or breast-feeding women depending on cohort.
Contact & Investigator
Francois-Clement BIDARD
PRINCIPAL INVESTIGATOR
Institut Curie
Frequently Asked Questions
Who can join the NCT05088395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05088395 currently recruiting?
Yes, NCT05088395 is actively recruiting participants. Contact the research team at drci.promotion@curie.fr for enrollment information.
Where is the NCT05088395 trial being conducted?
This trial is being conducted at Paris, France, Saint-Cloud, France.
Who is sponsoring the NCT05088395 clinical trial?
NCT05088395 is sponsored by Institut Curie. The principal investigator is Francois-Clement BIDARD at Institut Curie. The trial plans to enroll 2,050 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.